艾滋病药物可对抗热带寄生虫病
2011/5/9/10:1来源：前沿医学资讯网【慧聪制药工业网】据Science Daily网站报道，据一项发表在《FASEB Journal》上新的研究表明，科学家们发现，用于治疗艾滋病的药物或许将来会成为对抗寄生虫病的挽救生命药物，如利什曼病和疟疾等。科学家们已经确定了一些抗艾滋病病毒(HIV)药物的作用靶点，已知这些药物具有杀死致病性寄生虫的能力。虽然科学家们早就知道这些抗HIV药物可以杀死寄生虫，但先前尚不清楚其工作机制。研究人员发现，一种源于利什曼寄生虫特殊蛋白质Ddi 1对抗HIV抑制剂敏感。该研究在将来或许可以大大改变寄生虫病的治疗。
“发展中国家的人民面临着寄生虫病的危险，如疟疾和利什曼病。这些疾病带走了数百万人的生命，所以亟待需求对抗这些感染的新型有效的药物。”英国卡迪夫生物科学学院参与该研究的研究员ColinBerry博士说，“现有抗HIV药物的应用表明，一些寄生虫中存在潜在靶点，通过识别这些靶点蛋白质，我们希望能够利用寄生虫的这些薄弱点开发新型有效的治疗方法，从而来对抗来对这些破坏性疾病”。
科学家对缺乏Ddi 1蛋白质的酵母进行研究，发现其分泌高含量的蛋白质。加入利什曼原虫Ddi1蛋白能够使酵母恢复其正常低水平蛋白质的分泌。但是加入HIV蛋白酶抑制剂则反之，因为这些抑制剂能够阻断利什曼原虫Ddi1减少分泌物的能力，这表明Ddi 1蛋白与这些药物相互作用。
此外，当研究人员利用人类Ddi 1时，他们鉴定的那些能够良好阻断利什曼原虫蛋白活性的药物对人类的该蛋白作用明显较弱，这表明未来药物带来的副作用可能会减少。研究数据支持这一类化合物在利什曼病的潜在用途，但尚不支持现有上市化合物在临床上的应用。现有化合物的效力表明其或可为进一步探索化学作用的有用起点。
“如同HIV，寄生虫病仍然是全世界人类健康的严重威胁，”FASEB杂志主编Gerald Weissmann博士说，“每年数百万人死于这些疾病，我们迫切需求新的药物，专门用于对抗头号杀手HIV的药物，现在可能转而对抗诸如利什曼病和疟疾等寄生虫病”。
艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复
 |
||||
| 图示∶2010年12月即将出版的《中国特色医疗金鉴》登载的刘君主任及其机构 | ||||
|
||||
AIDS drugs are available against tropical parasitic diseases
2011/5/9/10: 1 Source: Frontier Medical News
【HC pharmaceutical industry Web site, according to Science Daily reported, according to a study published in the "FASEB Journal" on the new study, scientists found that drugs used to treat AIDS may be a fight against parasitic disease in future life-saving drugs such as leishmaniasis and malaria. Scientists have identified a number of anti-HIV (HIV) targets of drugs, these drugs are known to have the ability to kill pathogenic parasites. Although scientists have long known of these anti-HIV drugs can kill the parasites, but its mechanism is not clear earlier. The researchers found that a specific protein from the parasite Leishmania Ddi 1 against HIV inhibitor sensitive. The study in the future may significantly alter the treatment of parasitic diseases.
"People in developing countries face the risk of parasitic diseases such as malaria and leishmaniasis. These diseases take the lives of millions of people, so the urgent needs of new combat these infections and effective drug." Bio Cardiff Science researchers involved in the study, said Dr. ColinBerry, "the application of existing anti-HIV drugs that target a number of parasites in the potential, through the identification of these target proteins, we hope to take advantage of the weak points of these parasites to develop new and effective treatment, and thus to counter to these devastating diseases. "
Scientists lack Ddi 1 protein in yeast, and found that the secretion of high levels of protein. Leishmania Ddi1 added to the yeast protein can resume its normal low level of protein secretion. However, HIV protease inhibitors were added the other hand, because these inhibitors can block the secretion of Leishmania Ddi1 reduce the capacity, suggesting that Ddi 1 protein interactions with these drugs.
In addition, when the researchers used human Ddi 1, they identified those who can block a good biological activity of Leishmania drugs on the human role of the protein was weak, suggesting that future drug side effects may be reduced. Research data to support this type of compounds in the potential use of leishmaniasis, but the market does not yet support the existing compounds in clinical applications. The effect that the existing compounds, or can be useful to further explore the chemical starting point.
"Like HIV, parasitic diseases remain a serious threat to human health around the world," FASEB, Dr. Gerald Weissmann, editor says, "millions of people each year die from these diseases, we urgently need new drugs, designed to combat the number one killer of HIV drugs, may now turn to confrontation, such as malaria, leishmaniasis and parasitic diseases. "